BONESUPPORT HOLDING AB (BONEX) AI Stock Analysis

• Market Cap: kr20.98B
• Dividend Yield: N/A
• Average Volume (3M): 155.65K
• Price to Earnings (P/E): 140.5
• Beta (1Y): 0.21
• Revenue Growth: 44.52%
• EPS Growth: -49.29%
• Country: SE
• Employees: 140
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.80
• Shares Outstanding: 65,859,190
• 10 Day Avg. Volume: 119,984
• 30 Day Avg. Volume: 155,645
• PEG Ratio: -4.14
• Price to Book (P/B): 34.90
• Price to Sales (P/S): 28.25
• P/FCF Ratio: 423.67
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr271.05
• Price Target Upside: -16.14% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 74 Outperform
• Price Target: kr354.00 ▲(9.53% Upside)

BONESUPPORT HOLDING AB's strong financial performance, characterized by robust revenue growth and cash flow, is the primary driver of its stock score. Technical analysis indicates mixed trends with potential undervaluation, while the high P/E ratio suggests overvaluation concerns. The absence of earnings call data and corporate events limits further insights.

BONESUPPORT HOLDING AB Business Overview & Revenue Model

Company Description

BONESUPPORT HOLDING AB is a Swedish medical technology company specializing in the development and commercialization of innovative injectable bioceramic bone graft substitutes. The company's core products are primarily aimed at treating bone voids and bone defects, offering solutions in the orthopedic and trauma sectors. BONESUPPORT is recognized for its proprietary CERAMENT platform, which combines biocompatible materials with unique drug elution capabilities, enhancing bone healing and regeneration.

How the Company Makes Money

BONESUPPORT HOLDING AB generates revenue primarily through the sale of its CERAMENT line of injectable bioceramic bone graft substitutes. These products are distributed both directly and through strategic partnerships with medical device distributors and healthcare providers across various regions. The company's revenue streams are bolstered by its research and development efforts, which lead to product innovations and enhancements that meet the evolving needs of the orthopedic and trauma sectors. Additionally, BONESUPPORT may engage in collaborations with other healthcare companies to expand its market reach and product offerings, thereby contributing to its earnings. The company also benefits from clinical studies and regulatory approvals that enhance the credibility and adoption of its products in the global medical community.

BONESUPPORT HOLDING AB Financial Statement Overview

Summary

BONESUPPORT HOLDING AB displays strong financial health with consistent revenue growth, high profit margins, and a stable balance sheet marked by low leverage. Efficient cash flow management is evident, despite a move towards internal cash generation due to reduced external funding.

Income Statement

BONESUPPORT HOLDING AB demonstrates strong revenue growth, with a TTM (Trailing-Twelve-Months) revenue increase of 11% compared to the previous annual report. The company maintains impressive gross and net profit margins at 92.6% and 12.3%, respectively, showcasing efficient operations. However, a slight dip in EBIT margin from the previous year indicates room for improvement in operational efficiency. Overall, the income statement reflects a positive growth trajectory and profitability.

Balance Sheet

The company has a robust balance sheet with a low debt-to-equity ratio of 0.017, indicating minimal leverage risks. The equity ratio is strong at 82.7%, suggesting a high proportion of assets financed by equity. While the return on equity is modest at 16.5%, the company's low debt levels and high equity ratio provide financial stability and reduced risk exposure.

Cash Flow

BONESUPPORT HOLDING AB shows significant improvement in cash flow, with a notable increase in free cash flow and operating cash flow compared to the previous year. The operating cash flow to net income ratio of 0.78 and free cash flow to net income ratio of 0.74 reflect a healthy cash generation capability. However, the cash flow from financing activities remains negative, indicating a potential decrease in external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.06B	898.73M	591.08M	328.82M	212.88M	180.86M
Gross Profit	983.80M	832.25M	540.92M	297.71M	189.70M	161.60M
EBITDA	196.50M	185.75M	28.94M	-54.34M	-72.39M	-90.91M
Net Income	147.98M	133.75M	245.02M	-68.17M	-85.53M	-101.41M
Balance Sheet
Total Assets	962.82M	879.69M	688.82M	371.82M	343.92M	465.22M
Cash, Cash Equivalents and Short-Term Investments	309.68M	227.00M	167.35M	201.28M	206.46M	353.74M
Total Debt	12.68M	14.59M	17.48M	17.45M	21.42M	10.48M
Total Liabilities	166.11M	152.23M	143.64M	102.89M	78.22M	66.32M
Stockholders Equity	796.72M	727.46M	545.18M	268.93M	265.70M	398.90M
Cash Flow
Free Cash Flow	207.03M	59.92M	-24.32M	-50.26M	-86.84M	-102.93M
Operating Cash Flow	211.95M	65.76M	-18.26M	-46.98M	-83.42M	-100.28M
Investing Cash Flow	-5.56M	-6.26M	-6.06M	-3.28M	-3.42M	-2.66M
Financing Cash Flow	-5.73M	-4.81M	-6.70M	42.78M	-61.56M	365.34M

BONESUPPORT HOLDING AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 323.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BONEX, the sentiment is Negative. The current price of 323.2 is above the 20-day moving average (MA) of 320.37, above the 50-day MA of 290.77, and below the 200-day MA of 327.69, indicating a neutral trend. The MACD of 8.26 indicates Positive momentum. The RSI at 52.94 is Neutral, neither overbought nor oversold. The STOCH value of 10.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BONEX.

BONESUPPORT HOLDING AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BONEX	74 Outperform	kr20.98B	140.49	20.14%	―	44.52%	-49.29%
BIOA.B	71 Outperform	€19.21B	21.46	60.96%	―	501.62%	―
ALIF.B	66 Neutral	$20.52B	60.86	6.27%	0.45%	4.56%	185.59%
VIMIAN	57 Neutral	kr16.57B	66.45	3.34%	―	15.07%	117.65%
EKTA.B	55 Neutral	kr17.90B	75.54	2.43%	5.13%	-0.57%	-81.80%
VITR	54 Neutral	kr18.31B	40.24	3.46%	0.81%	0.14%	―
Sector *	52 Neutral	kr5.99B	9.29	-57.89%	2.12%	23.80%	21.79%

BONESUPPORT HOLDING AB Corporate Events

BONESUPPORT HOLDING AB Reports Strong Q2 2025 Growth and Leadership Transition

BONESUPPORT HOLDING AB reported strong growth in the US market for Q2 2025, with net sales increasing by 29% and significant sales growth in North America. The company’s CERAMENT G product continues to gain traction, supported by clinical evidence and increased awareness of its benefits in treating bone infections. The US Centers for Medicare & Medicaid Services proposed extended cost coverage for CERAMENT G, indicating its growing importance in orthopedic treatments. The company is also undergoing a leadership transition, with a new CEO set to take over in September 2025.

BONESUPPORT to Release Q2 2025 Interim Report with Webcast

BONESUPPORT HOLDING AB announced it will release its Q2 2025 interim report on July 15, followed by a conference call and webcast hosted by the CEO and CFO. This event will provide insights into the company’s performance and allow stakeholders to engage directly with the management, potentially impacting investor confidence and market positioning.

Incoming CEO of BONESUPPORT Acquires Shares, Signaling Confidence

BONESUPPORT announced that its incoming CEO, Torbjörn Sköld, has acquired 15,000 shares in the company, amounting to an investment of approximately 3.8 million SEK. This move signifies a strong commitment from the new leadership and could positively impact the company’s market confidence and stakeholder trust as Sköld prepares to assume his role in September 2025.

BONESUPPORT HOLDING AB Annual Shareholders’ Meeting Resolutions

BONESUPPORT HOLDING AB held its annual shareholders’ meeting where all proposed resolutions were passed. Key decisions included the re-election of board members, adjustments to board remuneration, and the authorization for the board to issue new shares to raise capital and support strategic initiatives. The meeting also approved a long-term incentive program for senior executives and key employees, aiming to align their interests with the company’s long-term performance goals.